Autor: Kozakiewicz, Andrzej - Katalog OPAC zbiorów

Skocz do pozycji: 1.

Tytuł:: Glioblastoma - actual knowledge and future perspectives
Glejak - aktualna wiedza oraz perspektywy
Autorzy:: Bilicki, Dominik
Zbrożek, Mikołaj
Fudalej, Marta
Deptała, Andrzej
Badowska-Kozakiewicz, Anna
Powiązania:: https://bibliotekanauki.pl/articles/2159008.pdf
Data publikacji:: 2022-06-30
Wydawca:: Medical Education
Tematy:: glioblastoma multiforme
oncology
miRna
pathogenesis
siRNA
glejak wielopostaciowy
onkologia
miRNA
patogeneza
Opis:: Glioblastoma is the most severe IV-class glioma and therefore the prognosis for patients remains poor despite some improvement in the treatment area. The neurological or psychiatric symptoms especially fast-developing ones should be fully investigated. This article aims to summarize actual knowledge of glioblastoma and present future perspectives. The underlying causes are usually associated with mutations of EGFR, PTEN, IDH1, p53 genes. The MRI scan, MGMT promoter methylation status, GFAP immunohistochemical detection and Karnofsky performance status are valuable diagnostic tools and some other potential biomarkers with high specificity are proposed. The standard of care is surgery and Stupp protocol which is the combination of radiotherapy and chemotherapy with temozolomide. Nevertheless, after remission the treatment possibilities are limited. Many efforts have been devoted to elaborate novel therapeutic strategies using e.g. CAR-T cells, nanoparticles, monoclonal antibodies, miRNA, siRNA or proteasome inhibitors.
Glejak wielopostaciowy klasyfikowany jest do grupy najbardziej złośliwych glejaków o IV stopniu złośliwości ze szczególnie niekorzystnymi prognozami związanymi z jego leczeniem. Pojawienie się u pacjenta szybko postępujących objawów zarówno psychiatrycznych, jak i neurologicznych powinno być zawsze dokładnie zbadane. Artykuł ma na celu zebranie oraz podsumowanie aktualnej wiedzy na temat glejaka oraz zaprezentowanie możliwych perspektyw rozwoju metod diagnostyczno-leczniczych. Rozwój glejaka ma zazwyczaj związek z mutacjami w genach EGFR, PTEN, IDH1 lub p53. Do użytecznych narzędzi diagnostycznych należą m.in. badanie MRI, analiza metylacji promotora genu MGMT oraz immunohistochemiczne oznacznie GFAP. W leczeniu glejaków wielopostaciowych najczęściej stosowanym schematem jest protokół Stuppa bazujący na połączeniu radioterapii z chemioterapią temozolomidem. Niemniej jednak, dalsze możliwości leczenia są limitowane. Zintegrowane wysiłki naukowców są ukierunkowane na poszukiwanie nowych strategii leczenia przy użyciu m.in. teraapii CAR-T, nanocząteczek, przeciwciał monoklonalnych, miRNA, siRNA oraz inhibitorów proteasomów
Źródło:: OncoReview; 2022, 12, 2; 35-44
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 2.

Tytuł:: The role of E2F2 in signaling pathways associated with cancer pathogenesis and potential treatment: A review of current studies
Autorzy:: Domańska, Julia
Poboży, Kamil
Domański, Paweł
Fudalej, Marta
Deptała, Andrzej
Badowska-Kozakiewicz, Anna
Powiązania:: https://bibliotekanauki.pl/articles/22792539.pdf
Data publikacji:: 2023-07
Wydawca:: Medical Education
Tematy:: E2F2
E2F
cancer
transcription factor
oncology
p53
p21
Opis:: Introduction and objective. E2F transcription factor 2 (E2F2) protein is the transcription factor that plays an important role in tumorigenesis. E2F2 effects the cell cycle, tumor suppressor proteins, and can also be transformed by proteins of small DNA tumor viruses. The objective of the study is to provide a summary of the current knowledge on the neoplastic pathways that involve E2F2. State of knowledge. Numerous studies have demonstrated a role for E2F2 in various signaling pathways. Certain components of these pathways may serve as potential targets for oncological therapy. E2F2 has been shown to be associated with neoplasms of various locations and histological types (breast, colon, gastric, laryngeal, liver, lung, ovarian, pancreatic, and prostate cancers). Conclusions. Further investigations of E2F2 pathways are warranted for a clearer understanding of neoplastic processes and to identify novel pharmacological treatments.
Źródło:: OncoReview; 2023, 13, 2; 58-66
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 3.

Tytuł:: ELF3 as an important factor in carcinogenesis – a brief review of the recent studies
Autorzy:: Domańska, Julia
Poboży, Kamil
Kuryłek, Michał
Fudalej, Marta M.
Sobiborowicz, Aleksandra
Deptała, Andrzej
Badowska-Kozakiewicz, Anna M.
Powiązania:: https://bibliotekanauki.pl/articles/1035652.pdf
Data publikacji:: 2020
Wydawca:: Medical Education
Tematy:: ELF3
carcinogenesis
molecular biology
Opis:: Introduction and objective: E74-like transcription factor 3 (ELF3) is mainly expressed in epithelial tissue, being responsible for differentiation and regeneration. Furthermore, it plays a role in inflammation, remodeling, allergy regulation and apoptosis. Various studies on ELF3 conducted since 1997 have also proved its connection with carcinogenesis and metastasis. This review summarizes recent advances in understanding the role of ELF3 in the following cancers: ampullary, bladder, breast, gastric, hepatocellular, nasopharyngeal, thyroid, lung and ovarian ones. State of knowledge: There are still many unresolved and undiscovered issues regarding ELF3 mutations, however, based on research since 2016, a link to many signaling pathways important for carcinogenesis has been shown. There is no simple correlation between a specific ELF3 mutation and effect on cancer cells. In various types of cancers, ELF3 is associated with other pathways, and modifications exerted by silencing or amplifying its or associated genes, cause different effects in patient prediction. An example of the effect of ELF3 on tumor progression is achieved by negatively regulating the ZEB1 transcription factor responsible for metastasis. WNT, RAS, Akt, mTOR, HER2, Cyclin D, IRF6 are other ELF3-related factors that affects pathways crucial for tumorigenesis. Conclusions: Further research and attempts to use ELF3 in the treatment and prognosis of cancer appear to be beneficial.
Źródło:: OncoReview; 2020, 10, 2; 77-81
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 4.

Tytuł:: The comparison between the two most common histological subtypes of breast cancer - invasive ductal and invasive lobular breast carcinoma
Autorzy:: Fudalej, Marta
Sobiborowicz-Sadowska, Aleksandra
Mormul, Agata
Jopek, Sylwia
Borowiec, Agnieszka
Sikorski, Piotr
Patera, Janusz
Deptała, Andrzej
Badowska-Kozakiewicz, Anna M.
Powiązania:: https://bibliotekanauki.pl/articles/44426576.pdf
Data publikacji:: 2024-04-07
Wydawca:: Medical Education
Tematy:: immunohistochemistry
invasive lobular carcinoma
invasive ductal carcinoma
Opis:: Introduction: Invasive lobular carcinoma (ILC) occurs in 5–15% of all cases of breast cancer. In most studies, it is found to be more common among older patients, form larger tumours and present with ill-defined margins, in comparison to invasive ductal carcinoma (IDC). Material and methods: Histological preparations were obtained from 651 patients suffering from breast cancer. Preparations stained with hematoxylin and eosin were used to identify tumour type and grading. Samples underwent a basic molecular profile evaluation encompassing ER (oestrogen receptor), PR (progesterone receptor) and human epidermal growth factor receptor 2 (HER2) expression. Results: 592 cases of IDC and 59 cases of ILC were detected. The median age was 60 in both groups. While there were no statistically significant differences between IDC and ILC in nodal status and tumour size for all age groups, IDC was more frequently diagnosed at higher grading (G3). G3 accounted for 32% of all IDC specimens compared to only 13% of ILC specimens. In both groups, the most prevalent combination of hormone receptors was ER+/PR+/HER2-. The differences in ER and PR expression were statistically significant; both were assessed as positive in most ILC cases and just over half of IDC. No HER2 amplification was noted in most cases in both cancer subtypes. Conclusions: In our study, IDC and ILC showed no difference with respect to patients’ median age at the diagnosis and local disease advancement defined by TNM. ILC cases were hormone-dependent and HER2-negative more frequently than IDC. Grade 3 tumours accounted for a higher proportion of IDC cases. This was in line with several other clinicopathological analyses of breast cancer. However, there are also several papers indicating ILC’s association with favourable prognostic features, not only in terms of hormone receptors and HER2 expression but also tumour size and nodal involvement. This underlines the fact that clear differences between IDC and ILC prognosis still cannot be established.
Źródło:: OncoReview; 2024, 14, 1; 9-15
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Informacja

Wyszukujesz frazę "Kozakiewicz, Andrzej" wg kryterium: Autor

Źródło danych

Dostawca treści

Kolekcja

Rok wydania

Wydawca

Temat

Autor

Typ dokumentu

Język